Evidence map›Paper›PMID 11799170›Full record

ArticleJournal of virology2002

Persistence and fitness of multidrug-resistant human immunodeficiency virus type 1 acquired in primary infection.

Bluma G Brenner, Jean-Pierre Routy, Marco Petrella, Daniela Moisi, Maureen Oliveira, Mervi Detorio, Bonnie Spira, Vidal Essabag, Brian Conway, Richard Lalonde and 2 more

Open access · greenAbstract readCase Reports
In one paragraph

Article in Journal of virology, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers.

0numbers the graph read from it
0cells of the map it votes in
51citing papers in PubMed
7.0field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

51 citing papers in PubMed, 220 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Comparison of the efficacy between once-monthly oral ibandronate and risedronate among Korean women with osteoporosis: a nationwide population-based study.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2019
    Article
  5. Neutral Theory and Rapidly Evolving Viral Pathogens.Molecular biology and evolution · 2018
    Article
  6. Article
  7. HIV-1 drug resistance and resistance testing.Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases · 2016
    Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Towards targeted screening for acute HIV infections in British Columbia.Journal of the International AIDS Society · 2011
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Bluma G BrennerMcGill University AIDS Centre, Jewish General Hospital, Montreal, Quebec, Canada.
Jean-Pierre Routy
Marco Petrella
Daniela Moisi
Maureen Oliveira
Mervi Detorio
Bonnie Spira
Vidal Essabag
Brian Conway
Richard Lalonde
Rafick-Pierre Sekaly
Mark A Wainberg
Jewish General Hospital · CAMcGill University Health Centre · CAUniversité de Montréal · CAUniversity of British Columbia · CA

Funding

INTEGRATED APPROACH TO ACUTE HIV INFECTIONR01AI043271 · NIAID · UNIVERSITY OF BRITISH COLUMBIA · PI CONWAY, BRIAN · 1999 to 2001
$910k
NIAID NIH HHS R01 AI43271-01
6 · The paper itself

Abstract

This study examines the persistence and fitness of multidrug-resistant (MDR) viruses acquired during primary human immunodeficiency virus infection (PHI). In four individuals, MDR infections persisted over the entire study period, ranging from 36 weeks to 5 years, in the absence of antiretroviral therapy. In stark contrast, identified source partners in two cases showed expected outgrowth of wild-type (WT) virus within 12 weeks of treatment interruption. In the first PHI case, triple-class MDR resulted in low plasma viremia (1.6 to 3 log copies/ml) over time compared with mean values obtained for an untreated PHI group harboring WT infections (4.1 to 4.3 log copies/ml). Increasing viremia in PHI patient 1 at week 52 was associated with the de novo emergence of a protease inhibitor-resistant variant through a recombination event involving the original MDR virus. MDR infections in two other untreated PHI patients yielded viremia levels typical of the untreated WT group. A fourth patient's MDR infection yielded low viremia (<50 to 500 copies/ml) for 5 years despite his having phenotypic resistance to all antiretroviral drugs in his treatment regimen. In two of these PHI cases, a rebound to higher levels of plasma viremia only occurred when the M184V mutation in reverse transcriptase could no longer be detected and, in a third case, nondetection of M184V was associated with an inability to isolate virus. To further evaluate the fitness of MDR variants acquired in PHI, MDR and corresponding WT viruses were isolated from index and source partners, respectively. Although MDR viral infectivity (50% tissue culture infective dose) was comparable to that observed for WT viruses, MDR infections in each case demonstrated 2-fold and 13- to 23-fold reductions in p24 antigen and reverse transcriptase enzymatic activity, respectively. In dual-infection competition assays, MDR viruses consistently demonstrated a marked replicative disadvantage compared with WT virus. These results indicate that MDR viruses that are generated following PHI can establish persistent infections as dominant quasispecies despite their impaired replicative competence.

Indexed as

Drug Resistance, Multiple, ViralAdultAnti-HIV AgentsHIV-1HIV InfectionsHumansMaleMicrobial Sensitivity TestsPhenotypeReverse Transcriptase InhibitorsVirus ReplicationAnti-HIV AgentsReverse Transcriptase Inhibitors

Identifiers

PMID11799170
PMCPMC135882
OpenAlexW2096494921

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.